AKCEA THERAPEUTICS, INC. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Revenue:
Research and development revenue under collaborative agreements
Total revenue
Product
Research and Development Revenue Under Collaborative Agreements
Licensing
Commercial Revenue
Total revenue
Expenses:
Cost of product/license
Product
Licensing
Cost of sales - intangible asset amortization
Research and development
General and administrative
Selling, general and administrative
Net loss share from commercial activities under arrangement with Ionis Pharmaceuticals, Inc.
Total expenses
Income (loss) from operations
Other income (expense):
Investment income
Interest expense
Other income
Other (expense) income
Income (loss) before income tax expense
Income tax expense
Net income (loss)
Common Stock
Preferred Stock
Total net income (loss)
Net loss per share, basic and diluted (in dollars per share)
Weighted-average shares outstanding, basic and diluted (in shares)
Net income (loss) per share of common stock, basic
Weighted-average shares of common stock outstanding, basic
Preferred Stock
Total weighted-average shares of common stock outstanding, basic

Comments